Inorder to study the combined effect of end-to-side portacaval shunt and chronic liver damage on biliary organic anion transport, the rat model of thioacetamide-induced chronic liver injury was utilized. Compared with sham-operated animals, bile flow and maximal biliary excretion (Tm) of sulfobromophthalein sodium (BSP) was decreased in rats 9 weeks after shunt operation. If rats with shunts were treated for 8 weeks with thioacetamide, an agent causing hepatic fïbrosis and pseudolobule formation, BSP transport from the hepatocyte into bile was further diminished. Compared with the shunted controls, the thioacetamide-treated rats with shunts had elevated serum bilirubin and alkaline phosphatase concentrations, and on electron microscopy their livers had dilated bile canaliculi with a decreased number of microvilli. Non-shunted rats treated with thioacetamide for 8 weeks had similar but less severe changes in the canalicular ultrastructure. Bile flow and BSP Tm were not influenced by thioacetamide treatment alone, perhaps due to the marked liver hypertrophy in these animals. These results indicate that canalicular active transport of organic anions is more sensitive to the effect of thioacetamide in animals with portacaval shunts than in those with sham operations. A similar impairment of hepatic organic anion handling by hepatotoxic compounds might be the consequence of portasystemic shunts in patients with liver cirrhosis.

Keywords:
Thioacetamide, Liver cirrhosis, Portacaval shunt, Bile flow, BSP excretion
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.